- In order to participate in this study, all subjects must meet ALL of the following inclusion criteria:
- * Individuals 50 to 64 years of age (i.e. 50 to ≤64 years) on the day of informed consent
- * Individuals who have voluntarily given written consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry
- * Individuals who can comply with study procedures including follow-up
- * Males, females of non-childbearing potential or females of childbearing potential who are using an effective birth control method, at least 30 days prior to informed consent, which they intend to use for at least 2 months after the study vaccination
Influenza, Human
A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age
NCT05044195 | PHASE 3 | INTERVENTIONAL
This Phase 3 study is a randomized, observer-blind immunogenicity and safety study of aQIV (an MF59-adjuvanted quadrivalent influenza vaccine) compared with a licensed quadrivalent influenza vaccine in adults 50 to 64 years of age.
Trial Information
If interested, contact clinicaltrials@cslbehring.com for more information
CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy
Coastal Clinical Research, Inc.
Mobile,Alabama,United States,36608
Alliance for Multispecialty Research
Tempe,Arizona,United States,85281
JEM Research Institute
Atlantis,Florida,United States,33462
Headlands Research Orlando
Orlando,Florida,United States,32819
Meridian Clinical Research
Savannah,Georgia,United States,31406
Meridian Clinical Research
Sioux City,Iowa,United States,51106
Alliance for Multispecialty Research
Kansas City,Missouri,United States,64114
Meridian Clinical Research
Lincoln,Nebraska,United States,68510
Meridian Clinical Research
Norfolk,Nebraska,United States,68701
Meridian Clinical Research
Omaha,Nebraska,United States,68134
United Medical Associates
Binghamton,New York,United States,13901
Meridian Clinical Research
Endwell,New York,United States,13760
Vee Family Doctors Centre
Paide,Estonia
Innomedica O Outpatient
Tallinn,Estonia
Al Mare Perearstikeskus O
Tallinn,Estonia
Merelahe Family Doctors Centre
Tallinn,Estonia
Center for Clinical and Basic Research
Tallinn,Estonia
Clinical Research Center Vaccine Trials
Tartu,Estonia
Klinische Forschung Berlin
Berlin,Germany
Emovis GmbH
Berlin,Germany
Klinische Forschung Dresden GmbH
Dresden,Germany
IKF Pneumologie GmbH & Co. KG
Frankfurt,Germany
Siteworks GmbH
Fulda,Germany
Klinische Forschung Hamburg GmbH
Hamburg,Germany
Clinical Research Hamburg GmbH
Hamburg,Germany
Klinische Forschung HannoverMitte GmbH
Hannover,Germany
Siteworks GmbH
Hannover,Germany
SIBAmed GmbH & Co KG
Leipzig,Germany
Studienzentrum Leitz Triderm
Stuttgart,Germany
Study Eligibility Criteria
Additional Studies
Additional studies can be found at ClinicalTrials.gov